↓ Skip to main content

Dove Medical Press

Article Metrics

Biosimilar medicines and cost-effectiveness

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, February 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
65 Dimensions

Readers on

mendeley
157 Mendeley
Title
Biosimilar medicines and cost-effectiveness
Published in
ClinicoEconomics and Outcomes Research: CEOR, February 2011
DOI 10.2147/ceor.s12494
Pubmed ID
Authors

Steven Simoens

Abstract

Given that biosimilars are agents that are similar but not identical to the reference biopharmaceutical, this study aims to introduce and describe specific issues related to the economic evaluation of biosimilars by focusing on the relative costs, relative effectiveness, and cost-effectiveness of biosimilars. Economic evaluation assesses the cost-effectiveness of a medicine by comparing the costs and outcomes of a medicine with those of a relevant comparator. The assessment of cost-effectiveness of a biosimilar is complicated by the fact that evidence needed to obtain marketing authorization from a registration authority does not always correspond to the data requirements of a reimbursement authority. In particular, this relates to the availability of adequately powered equivalence or noninferiority studies, the need for comparative data about the effectiveness in a real-world setting rather than the efficacy in a structured setting, and the use of health outcome measures instead of surrogate endpoints. As a biosimilar is likely to be less expensive than the comparator (eg, the reference biopharmaceutical), the assessment of the cost-effectiveness of a biosimilar depends on the relative effectiveness. If appropriately designed and powered clinical studies demonstrate equivalent effectiveness between a biosimilar and the comparator, then a cost-minimization analysis identifies the least expensive medicine. If there are differences in the effectiveness of a biosimilar and the comparator, other techniques of economic evaluation need to be employed, such as cost-effectiveness analysis or cost-utility analysis. Given that there may be uncertainty surrounding the long-term safety (ie, risk of immunogenicity and rare adverse events) and effectiveness of a biosimilar, the cost-effectiveness of a biosimilar needs to be calculated at multiple time points throughout the life cycle of the product.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 1%
Brazil 1 <1%
Netherlands 1 <1%
Italy 1 <1%
Ecuador 1 <1%
Germany 1 <1%
India 1 <1%
United Kingdom 1 <1%
Canada 1 <1%
Other 3 2%
Unknown 144 92%

Demographic breakdown

Readers by professional status Count As %
Student > Master 33 21%
Researcher 30 19%
Student > Bachelor 28 18%
Other 18 11%
Student > Ph. D. Student 12 8%
Other 23 15%
Unknown 13 8%
Readers by discipline Count As %
Medicine and Dentistry 43 27%
Agricultural and Biological Sciences 30 19%
Pharmacology, Toxicology and Pharmaceutical Science 24 15%
Chemistry 8 5%
Economics, Econometrics and Finance 8 5%
Other 28 18%
Unknown 16 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 May 2018.
All research outputs
#4,116,655
of 14,454,606 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#111
of 375 outputs
Outputs of similar age
#33,777
of 124,120 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#2
of 12 outputs
Altmetric has tracked 14,454,606 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 375 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 124,120 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.